REGN Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 38.89% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 21.47%. Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37% beat Johnson & Johnson's return on equity of 33.27%.

Regeneron Pharmaceuticals, Inc. has a consensus price target of $781.13, signalling upside risk potential of 8.07%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could grow by 0.03%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Regeneron Pharmaceuticals, Inc. has a beta of 0.369, which suggesting that the stock is 63.095% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.49%. Johnson & Johnson offers a yield of 2.54% to investors and pays a quarterly dividend of $1.30 per share. Regeneron Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.8B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Regeneron Pharmaceuticals, Inc.'s net income of $1.5B is lower than Johnson & Johnson's net income of $5.2B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.30x while Johnson & Johnson's PE ratio is 19.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 5.59x versus 5.33x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 38.89% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 31.72%. Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37% beat Eli Lilly & Co.'s return on equity of 106.26%.

Regeneron Pharmaceuticals, Inc. has a consensus price target of $781.13, signalling upside risk potential of 8.07%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.16%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Regeneron Pharmaceuticals, Inc. has a beta of 0.369, which suggesting that the stock is 63.095% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.49%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Regeneron Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.8B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Regeneron Pharmaceuticals, Inc.'s net income of $1.5B is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.30x while Eli Lilly & Co.'s PE ratio is 50.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 5.59x versus 15.57x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 38.89% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 33.68%. Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37% beat Merck & Co., Inc.'s return on equity of 39.63%.

Regeneron Pharmaceuticals, Inc. has a consensus price target of $781.13, signalling upside risk potential of 8.07%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.92 which suggests that it could grow by 4.99%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Regeneron Pharmaceuticals, Inc. has a beta of 0.369, which suggesting that the stock is 63.095% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.49%. Merck & Co., Inc. offers a yield of 3.21% to investors and pays a quarterly dividend of $0.81 per share. Regeneron Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.8B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Regeneron Pharmaceuticals, Inc.'s net income of $1.5B is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.30x while Merck & Co., Inc.'s PE ratio is 13.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 5.59x versus 3.98x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 38.89% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 21.32%. Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37% beat Pfizer Inc.'s return on equity of 10.84%.

Regeneron Pharmaceuticals, Inc. has a consensus price target of $781.13, signalling upside risk potential of 8.07%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Pfizer Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Pfizer Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Regeneron Pharmaceuticals, Inc. has a beta of 0.369, which suggesting that the stock is 63.095% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.49%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Regeneron Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.8B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Regeneron Pharmaceuticals, Inc.'s net income of $1.5B is lower than Pfizer Inc.'s net income of $3.6B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.30x while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 5.59x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.